{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:47:22Z","timestamp":1790380042309,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.ijpharm.2016.01.004","type":"journal-article","created":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T08:01:09Z","timestamp":1451980869000},"page":"186-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles"],"prefix":"10.1016","volume":"499","author":[{"given":"M.A.","family":"Collier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.J.","family":"Peine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Oghumu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Varikuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Borteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.L.","family":"Papenfuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"Sataoskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Bachelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.","family":"Ainslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2016.01.004_bib0005","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1086\/324161","article-title":"Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator","volume":"33","author":"Arevalo","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0010","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1086\/518172","article-title":"Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis","volume":"44","author":"Arevalo","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0015","unstructured":"Arno Therapeutics, 2009. Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl]Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma. ClinicalTrails.gov, NCT00978523."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0020","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1021\/mp900311x","article-title":"In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants","volume":"7","author":"Bachelder","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0025","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1021\/cb100399x","article-title":"Identification, in vitro activity and mode of action of phosphoinositide-dependent-1 kinase inhibitors as antifungal molecules","volume":"6","author":"Baxter","year":"2011","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0030","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jac\/dkh542","article-title":"Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4","volume":"55","author":"Bellocchio","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0035","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/jcp.24919","article-title":"GRP78\/BiP\/HSPA5\/Dna K is a universal therapeutic target for human disease","volume":"230","author":"Booth","year":"2015","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0040","doi-asserted-by":"crossref","first-page":"7957","DOI":"10.1021\/la400541e","article-title":"Electrospun acetalated dextran scaffolds for temporal release of therapeutics","volume":"29","author":"Borteh","year":"2013","journal-title":"Langmuir"},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0045","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1073\/pnas.0901592106","article-title":"Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy","volume":"106","author":"Broaders","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0050","doi-asserted-by":"crossref","first-page":"e2603","DOI":"10.1371\/journal.pntd.0002603","article-title":"Five-year field results and long-term effectiveness of 20mg\/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India","volume":"8","author":"Burza","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0055","unstructured":"CDC, 2013. Leishmaniasis FAQs, CDC.gov."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0060","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1128\/EC.00235-12","article-title":"Cryptococcus neoformans phosphoinositide-dependent kinase 1 (PDK1) ortholog is required for stress tolerance and survival in murine phagocytes","volume":"12","author":"Chabrier-Rosello","year":"2013","journal-title":"Eukaryot. Cell"},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0065","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.1128\/AAC.00555-09","article-title":"Eradication of intracellular Salmonella enterica serovar Typhimurium with a small-molecule, host cell-directed agent","volume":"53","author":"Chiu","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0070","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1423-0127-16-110","article-title":"Eradication of intracellular Francisella tularensis in THP-1 human macrophages with a novel autophagy inducing agent","volume":"16","author":"Chiu","year":"2009","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0075","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1128\/AAC.00048-09","article-title":"Pharmacological exploitation of an off-target antibacterial effect of the cyclooxygenase-2 inhibitor celecoxib against Francisella tularensis","volume":"53","author":"Chiu","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0080","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1586\/14787210.2013.845524","article-title":"Delivery of host cell-directed therapeutics for intracellular pathogen clearance","volume":"11","author":"Collier","year":"2013","journal-title":"Expert Rev. Anti-infect. Ther."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0085","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1006\/phrs.2001.0825","article-title":"Flow cytometry, a useful tool for detecting the lethal effect of pentamidine on Leishmania viannia complex promastigote forms","volume":"44","author":"Delgado","year":"2001","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0090","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.2741\/4079","article-title":"Immunotherapy for tuberculosis: what\u2019s the better choice?","volume":"17","author":"Guo","year":"2012","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0095","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.vaccine.2005.08.095","article-title":"Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults","volume":"24","author":"Halperin","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/CMR.14.2.229-243.2001","article-title":"Leishmaniasis: current status of vaccine development","volume":"14","author":"Handman","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0105","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ijpharm.2014.10.022","article-title":"Acetalated dextran encapsulated AR-12 as a host-directed therapy to control Salmonella infection","volume":"477","author":"Hoang","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0110","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1242\/jcs.121814","article-title":"Poly(lactide-co-glycolide)-rifampicin nanoparticles efficiently clear Mycobacterium bovis BCG infection in macrophages and remain membrane-bound in phago-lysosomes","volume":"126","author":"Kalluru","year":"2013","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0115","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpharm.2012.04.043","article-title":"Enhanced stability of horseradish peroxidase encapsulated in acetalated dextran microparticles stored outside cold chain conditions","volume":"431","author":"Kanthamneni","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0120","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1021\/am3008888","article-title":"Synthesis and characterization of acetalated dextran polymer and microparticles with ethanol as a degradation product","volume":"4","author":"Kauffman","year":"2012","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0125","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ijpara.2007.04.007","article-title":"The amastigote forms of Leishmania are experts at exploiting host cell processes to establish infection and persist","volume":"37","author":"Kima","year":"2007","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0130","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1128\/AAC.03778-14","article-title":"Sensitization of intracellular Salmonella enterica serovar Typhimurium to aminoglycosides in vitro and in vivo by a host-targeted antimicrobial agent","volume":"58","author":"Lo","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0135","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1002\/eji.200939678","article-title":"IL-24 protects against Salmonella typhimurium infection by stimulating early neutrophil Th1 cytokine production, which in turn activates CD8+ T cells","volume":"39","author":"Ma","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0140","doi-asserted-by":"crossref","first-page":"19666","DOI":"10.1073\/pnas.1319659110","article-title":"Chronic arsenic exposure and microbial drug resistance","volume":"110","author":"McConville","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0145","doi-asserted-by":"crossref","first-page":"e1219","DOI":"10.1371\/journal.pntd.0001219","article-title":"Leishmaniasis: Middle East and North Africa research and development priorities","volume":"5","author":"McDowell","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0150","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.exppara.2013.08.004","article-title":"Miltefosine resistance in Leishmania donovani involves suppression of oxidative stress-induced programmed cell death","volume":"135","author":"Mishra","year":"2013","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0155","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.parint.2009.07.002","article-title":"In vivo induction of the autophagic machinery in human bone marrow cells during Leishmania donovani complex infection","volume":"58","author":"Mitroulis","year":"2009","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0160","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.antiviral.2015.05.003","article-title":"Inhibitors of cellular kinases with broad-spectrum antiviral activity for hemorrhagic fever viruses","volume":"120","author":"Mohr","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0165","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.1128\/IAI.68.11.6294-6299.2000","article-title":"Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulation","volume":"68","author":"Murray","year":"2000","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0170","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1365-2613.2001.00199.x","article-title":"Tissue granuloma structure\u2013function in experimental visceral leishmaniasis","volume":"82","author":"Murray","year":"2001","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0175","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1128\/AAC.47.8.2513-2517.2003","article-title":"Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis","volume":"47","author":"Murray","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0180","doi-asserted-by":"crossref","first-page":"e1674","DOI":"10.1371\/journal.pntd.0001674","article-title":"Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial","volume":"6","author":"Musa","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0005-2736(95)00188-3","article-title":"Is control of distribution of liposomes between tumors and bone marrow possible?","volume":"1278","author":"Nagayasu","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0190","unstructured":"National Institute of Biomedical Imaging and Bioengineering, 2015. Drug Delivery Systems: Getting Drugs to Their Targets in a Controlled Manner."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0195","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.2353\/ajpath.2010.100367","article-title":"Activation of phosphatidylinositol 3-kinase\/Akt and impairment of nuclear factor-kappaB: molecular mechanisms behind the arrested maturation\/activation state of Leishmania infantum-infected dendritic cells","volume":"177","author":"Neves","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0200","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1745-6215-12-166","article-title":"Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial","volume":"12","author":"Omollo","year":"2011","journal-title":"Trials"},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0205","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1586\/erv.10.89","article-title":"Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses","volume":"9","author":"Oyewumi","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0210","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4103\/0028-3886.35687","article-title":"Immunotherapy for fungal infections with special emphasis on central nervous system infections","volume":"55","author":"Parameswaran","year":"2007","journal-title":"Neurol. India"},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0215","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/mp300643d","article-title":"Efficient delivery of the toll-like receptor agonists polyinosinic:polycytidylic acid and CpG to macrophages by acetalated dextran microparticles","volume":"10","author":"Peine","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0220","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/jac\/dkt320","article-title":"Liposomal resiquimod for the treatment of Leishmania donovani infection","volume":"69","author":"Peine","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0225","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.micinf.2008.11.006","article-title":"Induction of autophagy correlates with increased parasite load of Leishmania amazonensis in BALB\/c but not C57BL\/6 macrophages","volume":"11","author":"Pinheiro","year":"2009","journal-title":"Microbes Infect.\/Instit. Pasteur"},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0230","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1128\/AAC.00030-11","article-title":"Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani","volume":"56","author":"Purkait","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0235","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1128\/IAI.00736-09","article-title":"Toll-like receptor 3 agonist protection against experimental Francisella tularensis respiratory tract infection","volume":"78","author":"Pyles","year":"2010","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0240","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1042\/bj20031253","article-title":"Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis","volume":"377","author":"Rejman","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0245","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0035-9203(03)90167-2","article-title":"Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline","volume":"97","author":"Rijal","year":"2003","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0250","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1462-5822.2006.00769.x","article-title":"Leishmania promastigotes activate PI3K\/Akt signalling to confer host cell resistance to apoptosis","volume":"9","author":"Ruhland","year":"2007","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0255","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0166-6851(86)90001-0","article-title":"Mechanism of action of amphotericin B on Leishmania donovani promastigotes","volume":"19","author":"Saha","year":"1986","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0260","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fimmu.2014.00296","article-title":"Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects","volume":"5","author":"Singh","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0265","doi-asserted-by":"crossref","first-page":"666","DOI":"10.4269\/ajtmh.1993.48.666","article-title":"Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma","volume":"48","author":"Squires","year":"1993","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0270","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1093\/infdis\/172.6.1627","article-title":"Effect of treatment with interferon-gamma alone in visceral leishmaniasis","volume":"172","author":"Sundar","year":"1995","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0275","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/516526","article-title":"Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis","volume":"176","author":"Sundar","year":"1997","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0280","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/380971","article-title":"Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations","volume":"38","author":"Sundar","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0285","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(10)62050-8","article-title":"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial","volume":"377","author":"Sundar","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0290","first-page":"109","article-title":"Development and differentiation of macrophages and their related cells","volume":"7","author":"Takahashi","year":"1994","journal-title":"Hum. Cell"},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0295","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1440-1827.1996.tb03641.x","article-title":"Development and heterogeneity of macrophages and their related cells through their differentiation pathways","volume":"46","author":"Takahashi","year":"1996","journal-title":"Pathol. Int."},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0300","doi-asserted-by":"crossref","first-page":"e18873","DOI":"10.1371\/journal.pone.0018873","article-title":"Influence of clinical status and parasite load on erythropoiesis and leucopoiesis in dogs naturally infected with leishmania (Leishmania) chagasi","volume":"6","author":"Tropia de Abreu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpharm.2016.01.004_bib0305","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1099\/00222615-25-3-197","article-title":"Lipopolysaccharide-induced non-specific resistance to systemic Escherichia coli infection in mice","volume":"25","author":"Vuopio-Varkila","year":"1988","journal-title":"J. Med. Microbiol."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517316300084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517316300084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T10:54:50Z","timestamp":1537095290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517316300084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":61,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0378517316300084"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2016.01.004","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2016.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}